Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David A Barbie

Showing results (91-100 of 120) with videos related to

Pageof 12
Sort By:
The Journal of Clinical Investigation|November 5, 2020
Dynamic single-cell RNA sequencing identifies immunotherapy persister cells following PD-1 blockadeKartik Sehgal, Andrew Portell, Elena V Ivanova, et al.
Cancer Immunology Research|May 28, 2015
Long-term Benefit of PD-L1 Blockade in Lung Cancer Associated with JAK3 ActivationEliezer M Van Allen, Hadrien G Golay, Yan Liu, et al.
Nature|October 9, 2024
AKT and EZH2 inhibitors kill TNBCs by hijacking mechanisms of involutionAmy E Schade, Naiara Perurena, Yoona Yang, et al.
Immunity|December 13, 2023
Single-cell functional genomics reveals determinants of sensitivity and resistance to natural killer cells in blood cancersOlli Dufva, Sara Gandolfi, Jani Huuhtanen, et al.
Molecular Cancer|March 16, 2024
Affinity fine-tuning anti-CAIX CAR-T cells mitigate on-target off-tumor side effectsYufei Wang, Alicia Buck, Brandon Piel, et al.
Nature Cancer|July 10, 2023
ALK peptide vaccination restores the immunogenicity of ALK-rearranged non-small cell lung cancerInes Mota, Enrico Patrucco, Cristina Mastini, et al.
Nature Genetics|August 29, 2018
Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumorsDiana Miao, Claire A Margolis, Natalie I Vokes, et al.
Cancer Discovery|January 22, 2014
Inhibition of KRAS-driven tumorigenicity by interruption of an autocrine cytokine circuitZehua Zhu, Amir R Aref, Travis J Cohoon, et al.
Molecular Cell|July 7, 2015
Metabolic Rewiring by Oncogenic BRAF V600E Links Ketogenesis Pathway to BRAF-MEK1 SignalingHee-Bum Kang, Jun Fan, Ruiting Lin, et al.
JCI Insight|January 23, 2026
EGFR-mutant transformed small cell lung cancer harbors intratumoral heterogeneity targetable with MEK inhibitor combination therapyAtsuko Ogino, Amir Vajdi, Xinmeng Jasmine Mu, et al.
Pageof 12

Showing results (91-100 of 120) with videos related to

Sort By:
Pageof 12
The Journal of Clinical Investigation|November 5, 2020
Dynamic single-cell RNA sequencing identifies immunotherapy persister cells following PD-1 blockadeKartik Sehgal, Andrew Portell, Elena V Ivanova, et al.
Cancer Immunology Research|May 28, 2015
Long-term Benefit of PD-L1 Blockade in Lung Cancer Associated with JAK3 ActivationEliezer M Van Allen, Hadrien G Golay, Yan Liu, et al.
Nature|October 9, 2024
AKT and EZH2 inhibitors kill TNBCs by hijacking mechanisms of involutionAmy E Schade, Naiara Perurena, Yoona Yang, et al.
Immunity|December 13, 2023
Single-cell functional genomics reveals determinants of sensitivity and resistance to natural killer cells in blood cancersOlli Dufva, Sara Gandolfi, Jani Huuhtanen, et al.
Molecular Cancer|March 16, 2024
Affinity fine-tuning anti-CAIX CAR-T cells mitigate on-target off-tumor side effectsYufei Wang, Alicia Buck, Brandon Piel, et al.
Nature Cancer|July 10, 2023
ALK peptide vaccination restores the immunogenicity of ALK-rearranged non-small cell lung cancerInes Mota, Enrico Patrucco, Cristina Mastini, et al.
Nature Genetics|August 29, 2018
Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumorsDiana Miao, Claire A Margolis, Natalie I Vokes, et al.
Cancer Discovery|January 22, 2014
Inhibition of KRAS-driven tumorigenicity by interruption of an autocrine cytokine circuitZehua Zhu, Amir R Aref, Travis J Cohoon, et al.
Molecular Cell|July 7, 2015
Metabolic Rewiring by Oncogenic BRAF V600E Links Ketogenesis Pathway to BRAF-MEK1 SignalingHee-Bum Kang, Jun Fan, Ruiting Lin, et al.
JCI Insight|January 23, 2026
EGFR-mutant transformed small cell lung cancer harbors intratumoral heterogeneity targetable with MEK inhibitor combination therapyAtsuko Ogino, Amir Vajdi, Xinmeng Jasmine Mu, et al.
Pageof 12